[go: up one dir, main page]

SK17512000A3 - Liek na liečenie nepoddajnej depresie a farmaceutická kompozícia - Google Patents

Liek na liečenie nepoddajnej depresie a farmaceutická kompozícia Download PDF

Info

Publication number
SK17512000A3
SK17512000A3 SK1751-2000A SK17512000A SK17512000A3 SK 17512000 A3 SK17512000 A3 SK 17512000A3 SK 17512000 A SK17512000 A SK 17512000A SK 17512000 A3 SK17512000 A3 SK 17512000A3
Authority
SK
Slovakia
Prior art keywords
treatment
component
effective amount
depression
combination
Prior art date
Application number
SK1751-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Gary Dennis Tollefson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK17512000A3 publication Critical patent/SK17512000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Percussion Or Vibration Massage (AREA)
SK1751-2000A 1998-05-22 1999-05-21 Liek na liečenie nepoddajnej depresie a farmaceutická kompozícia SK17512000A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8644498P 1998-05-22 1998-05-22
PCT/US1999/011276 WO1999061027A1 (en) 1998-05-22 1999-05-21 Combination therapy for treatment of refractory depression

Publications (1)

Publication Number Publication Date
SK17512000A3 true SK17512000A3 (sk) 2002-02-05

Family

ID=22198612

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1751-2000A SK17512000A3 (sk) 1998-05-22 1999-05-21 Liek na liečenie nepoddajnej depresie a farmaceutická kompozícia

Country Status (24)

Country Link
EP (1) EP0958824A3 (zh)
JP (1) JP2002516282A (zh)
KR (1) KR20010043730A (zh)
CN (1) CN1154496C (zh)
AU (1) AU761510B2 (zh)
BR (1) BR9911049A (zh)
CA (1) CA2332814C (zh)
CZ (1) CZ20004279A3 (zh)
EA (1) EA004539B1 (zh)
HK (1) HK1040055B (zh)
HR (1) HRP20000797A2 (zh)
HU (1) HUP0101901A3 (zh)
ID (1) ID26861A (zh)
IL (1) IL139592A (zh)
MY (1) MY127938A (zh)
NO (1) NO20005885L (zh)
NZ (1) NZ507980A (zh)
PL (1) PL344331A1 (zh)
SK (1) SK17512000A3 (zh)
TR (1) TR200003443T2 (zh)
TW (1) TWI226829B (zh)
UA (1) UA78181C2 (zh)
WO (1) WO1999061027A1 (zh)
ZA (1) ZA200006815B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030648A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
EP1782813A1 (en) * 1999-12-06 2007-05-09 H.Lundbeck A/S The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
NZ526801A (en) * 2001-01-02 2005-07-29 Upjohn Co Norepinephrine reuptake inhibitor i.e. reboxetine and neuroleptic to treat disorders of the central nervous system
AU2003268026A1 (en) * 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
KR100858852B1 (ko) 2002-12-27 2008-09-17 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
BRPI0413750A (pt) * 2003-09-04 2006-10-24 Lundbeck & Co As H uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit
EA200801812A1 (ru) 2003-09-17 2009-06-30 Янссен Фармацевтика Н.В. Сопряженные гетероциклические соединения
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
JP2007513896A (ja) * 2003-12-15 2007-05-31 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
ATE540941T1 (de) 2006-06-16 2012-01-15 Lundbeck & Co As H 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen
EP2120878B1 (en) * 2007-02-09 2014-07-30 Alphapharm PTY LTD A dosage form containing two active pharmaceutical ingredients in different physical forms
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN105769875A (zh) * 2014-12-22 2016-07-20 扬子江药业集团上海海尼药业有限公司 复方奥氮平盐酸氟西汀胶囊的制备方法
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
HUP9903679A3 (en) * 1996-03-11 2001-10-29 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder
NZ332039A (en) * 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
HUP0101901A3 (en) 2002-06-28
CA2332814A1 (en) 1999-12-02
UA78181C2 (en) 2007-03-15
CN1154496C (zh) 2004-06-23
CA2332814C (en) 2008-11-04
MY127938A (en) 2007-01-31
NZ507980A (en) 2003-10-31
EA004539B1 (ru) 2004-06-24
IL139592A (en) 2005-08-31
HRP20000797A2 (en) 2001-10-31
NO20005885D0 (no) 2000-11-21
ID26861A (id) 2001-02-15
WO1999061027A1 (en) 1999-12-02
HUP0101901A2 (hu) 2001-11-28
JP2002516282A (ja) 2002-06-04
KR20010043730A (ko) 2001-05-25
EP0958824A3 (en) 1999-12-01
EA200001218A1 (ru) 2001-06-25
AU4008699A (en) 1999-12-13
HK1040055A1 (zh) 2002-05-24
BR9911049A (pt) 2001-02-06
IL139592A0 (en) 2002-02-10
PL344331A1 (en) 2001-11-05
TWI226829B (en) 2005-01-21
HK1040055B (zh) 2005-04-01
AU761510B2 (en) 2003-06-05
NO20005885L (no) 2001-01-17
ZA200006815B (en) 2002-01-14
EP0958824A2 (en) 1999-11-24
CZ20004279A3 (cs) 2001-09-12
CN1311681A (zh) 2001-09-05
TR200003443T2 (tr) 2001-03-21

Similar Documents

Publication Publication Date Title
AU719033B2 (en) Combination therapy for treatment of psychoses
AU756468B2 (en) Combination therapy for treatment of bipolar disorders
SK17512000A3 (sk) Liek na liečenie nepoddajnej depresie a farmaceutická kompozícia
US6960577B2 (en) Combination therapy for treatment of refractory depression
US20030027817A1 (en) Combination therapy for treatment of bipolar disorders
EP0759299B1 (en) Potentiation of serotonin response
MXPA00011353A (es) Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria
EP1256345A1 (en) Combination therapy for treatment of psychoses
HK1009755B (zh) 治疗精神病的综合疗法
MXPA00011354A (en) Combination therapy for treatment of bipolar disorders